yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
Cloud Expo & Virtualization 2009 East
Smarter Business Solutions Through Dynamic Infrastructure
Smarter Insights: How the CIO Becomes a Hero Again
Windows Azure
Why VDI?
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun's Incubation Platform: Helping Startups Serve the Enterprise
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
OriGene Publishes Landmark Paper on Revolutionary Proteome Platform for Antibody Specificity Test
Key Publication Further Validates OriGene's Unique Approach and Application of Protein Microarray Technology to Analyze Antibody Specificity

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene"), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies.  Specificity of antibodies for research or clinical applications is of critical importance and therefore it is a "must" to demonstrate antibody specificity with high confidence.  Leveraging more than ten years of product development expertise, OriGene has generated a breakthrough mammalian-cell expressed antigen chip which contains greater than 50% of the human proteome ("Protein Microarray Technology").  OriGene's Protein Microarray Technology key utility is to verify diagnostic and therapeutic antibody specificity and identify cross-reactivity.  Antibody cross-reactivity is a major cause of concern throughout the industry with the development and commercialization of diagnostic and therapeutic antibodies. 


As published in BMC Biotechnology 2012, 12:88, OriGene's Protein Microarray Technology chip was successfully used to evaluate the specificity of the commonly used anti-ERCC1 antibody called 8F1.  This ERCC1 antibody is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy.  OriGene was able to utilize its proprietary technology to determine that the 8F1 antibody cross-reacts with a previously unknown nuclear protein called PCYT1A and thus is not suitable for use in IHC assays for ERCC1 detection. (view Abstract)

"This result is important, as it could explain some of the inconsistencies seen in comparative studies done on the 8F1 antibody. Using antibodies which cross-react with a nuclear protein PCYT1A when testing for ERCC1 may potentially lead to an incorrect IHC test result," says Wei-Wu He, Ph.D., who is CEO of OriGene and one of the co-authors of the scientific study.

OriGene utilized its Protein Microarray Technology to screen 18 monoclonal antibodies to identify two unique UltraMAB™ antibody clones, 4F9 and 2E12, and confirmed that these are truly "mono-specific." Every UltraMAB™ antibody is validated for IHC and for immunoassay analysis, and verified to have non-specific cross-reactivity by utilizing OriGene's Protein Microarray Technology. Consequently, each UltraMAB™ is specificity verified to an unprecedented level, ensuring superior performance for IHC applications.  In 2012, OriGene generated over 20 UltraMAB™ antibodies and its future plans are to launch new UltraMAB™ antibodies on a regular basis. 

Detailed information about the Protein Microarray Technology and a complete listing of the UltraMAB™ antibody product line is available at, where customers can learn more about OriGene's unique approach to ultra-specific monoclonal antibody development.  

About OriGene
OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide.  OriGene's research business offers one of the world's largest collections of cDNA clones, human proteins, antibodies and assays for use to study gene functions.  Leveraging the recent advances in the human genome, OriGene utilizes its innovative R&D in the U.S. and large scale capacity in China to produce an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significantly value added diagnostic benefits for disease screening and personalized medicine treatment. OriGene's Protein Microarray Technology is used for QC diagnostic and therapeutic specificity and other protein-protein interactions.   For more information, visit

SOURCE OriGene Technologies, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness....
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challen...
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve relia...
Achim Weiss is Chief Executive Officer and co-founder of ProfitBricks. In 1995, he broke off his studies to co-found the web hosting company "Schlund+Partner." The company "Schlund+Partner" later became the 1&1 web hosting product line. From 1995 to 2008, he was the technical dir...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevO...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers